Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience

Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience

Background: Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluated its safety and efficacy in our real-world population. Methods: We identified...

Full description

Bibliographic Details
Main Authors: Nicolò Matteo Luca Battisti, Frances Rogerson, Karla Lee, Scott Shepherd, Kabir Mohammed, Nicholas Turner, Sophie McGrath, Alicia Okines, Marina Parton, Stephen Johnston, Mark Allen, Alistair Ring
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Breast cancer
HER2-positive
Advanced, T-DM1
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294220300253

Internet

http://www.sciencedirect.com/science/article/pii/S2468294220300253

Similar Items